Magnetic albumin immuno-nanospheres as an efficient gene delivery system for a potential use in lung cancer: preparation, in vitro targeting and biological effect analysis.
Magnetic albumin immuno-nanospheres (MAINs), simultaneously loaded with super-paramagnetic iron oxide nanoparticles for targeting application and anticancer gene, plasmid-survivin/shRNA (pshRNA) and modified with anti-EGFR monoclonal antibody Cetuximab for targeting and treatment agents, were prepared for targeting lung cancer. Transmission electron microscopy images and transfection photographs, respectively, showed that magnetic nanoparticles and pshRNA were successfully encased in the albumin nanospheres. The release profiles in vitro indicated that nanospheres had an obvious effect of sustained release of pshRNA. The results of slide agglutination test and immunofluorescence analysis demonstrated that the immuno-nanospheres retained the immuno-reactivity of Cetuximab. The MAINs significantly increased adherence and uptake by GLC-82 lung cancer cells over-expressed epidermal growth factor receptor over a magnetic albumin nanospheres (MANs) control. The pshRNA-loaded MAINs formulation was more effective than equimolar doses of free Cetuximab, single magnetic targeting with pshRNA (pshRNA-loaded MANs) or single monoclonal antibody targeting with pshRNA (pshRNA-loaded AINs) in the treatment of GLC-82 lung cancer cells. Collectively, the study indicates that the novel pshRNA-loaded magnetic immuno-nanospheres represent a promising approach for magnetic and monoclonal antibody-dependent gene targeting in lung cancer therapy.
a School of Medicine of Southeast University , Nanjing , Jiangsu , P.R. China .|b School of Medicine of Henan Polytechnic University , Jiaozuo , Henan , P.R. China , and.
Xinxin
X
Hou
a School of Medicine of Southeast University , Nanjing , Jiangsu , P.R. China .
Hao
H
Zhang
c Department of Ultrasound in Medicine , The First Affiliated Hospitial (Jiangsu Province of TCM), Nanjing University of Chinese Medicine , Nanjing , Jiangsu , P.R. China.
Hongbo
H
Li
a School of Medicine of Southeast University , Nanjing , Jiangsu , P.R. China .
Dongsheng
D
Zhang
D045744:Cell Line, Tumor; D000068818:Cetuximab / Q000008:administration & dosage / Q000627:therapeutic use; D004317:Doxorubicin / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use; D065546:Drug Liberation; D066246:ErbB Receptors / Q000378:metabolism; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D058185:Magnetite Nanoparticles / Q000008:administration & dosage / Q000737:chemistry* / Q000648:ultrastructure; D054118:Nanospheres / Q000008:administration & dosage / Q000737:chemistry* / Q000378:metabolism / Q000648:ultrastructure; D010957:Plasmids / Q000008:administration & dosage; D034741:RNA, Small Interfering / Q000008:administration & dosage* / Q000737:chemistry / Q000627:therapeutic use; D012710:Serum Albumin, Bovine / Q000008:administration & dosage*; D000077022:Survivin; D014162:Transfection / Q000379:methods*
C107489:BIRC5 protein, human; D051034:Inhibitor of Apoptosis Proteins; D058185:Magnetite Nanoparticles; D034741:RNA, Small Interfering; D000077022:Survivin; D012710:Serum Albumin, Bovine; D004317:Doxorubicin; D066246:ErbB Receptors; D000068818:Cetuximab
Cetuximab; magnetic albumin immuno-nanospheres; survivin/shRNA